Search Results for "R"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for R. Results 911 to 920 of 1003 total matches.

Oral Contraceptives

   
The Medical Letter on Drugs and Therapeutics • May 15, 2000  (Issue 1078)
., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D., University of Manitoba EDITORIAL FELLOWS: Richard ...
Two types of oral contraceptives are available in the USA: combination oral contraceptives that contain both an estrogen and a progestin, and progestin-only contraceptives, or "mini-pills."Used as directed, all oral contraceptives marketed in the USA are similarly effective in preventing pregnancy.
Med Lett Drugs Ther. 2000 May 15;42(1078):42-4 |  Show IntroductionHide Introduction

Cholesterol Rethink for High-Risk Patients

   
The Medical Letter on Drugs and Therapeutics • May 10, 2004  (Issue 1182)
Hospital, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D ...
The recent "PROVE IT" trial in patients with coronary heart disease showed clinical benefits associated with reducing LDL cholesterol concentrations lower than the 100 mg/dL (2.59 mmol/L) or less that had been considered optimal.
Med Lett Drugs Ther. 2004 May 10;46(1182):37-9 |  Show IntroductionHide Introduction

Natalizumab (Tysabri) for Relapsing Multiple Sclerosis

   
The Medical Letter on Drugs and Therapeutics • Feb 14, 2005  (Issue 1202)
., University Hospital, Copenhagen Dan M. Roden, M.D., Vanderbilt University School of Medicine F. Estelle R ...
Natalizumab, a recombinant humanized monoclonal antibody, has received accelerated approval from the FDA for intravenous treatment of relapsing forms of multiple sclerosis (MS). The beta interferons and glatiramer acetate are widely used for treatment of MS; they generally reduce the number of relapses by about 30% compared to placebo, and have been shown to be safe and effective for periods ranging from 4 to 10 years.
Med Lett Drugs Ther. 2005 Feb 14;47(1202):13-5 |  Show IntroductionHide Introduction

Solifenacin and Darifenacin for Overactive Bladder

   
The Medical Letter on Drugs and Therapeutics • Mar 14, 2005  (Issue 1204)
, Copenhagen Dan M. Roden, M.D., Vanderbilt School of Medicine F. Estelle R. Simons, M.D., University ...
Solifenacin succinate (VESIcare - Yamanouchi and GlaxoSmithKline) and darifenacin hydrobromide (Enablex - Novartis) have been approved by the FDA for oral treatment of overactive bladder.
Med Lett Drugs Ther. 2005 Mar 14;47(1204):23-4 |  Show IntroductionHide Introduction

Azithromycin Extended-Release (Zmax) for Sinusitis and Pneumonia

   
The Medical Letter on Drugs and Therapeutics • Sep 28, 2005  (Issue 1218)
., Vanderbilt School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D ...

Zmax (Pfizer), an extended-release oral suspension of azithromycin, has been approved by the FDA for single dose treatment of mild to moderate community acquired pneumonia (CAP) and acute bacterial sinusitis (ABS) in adults. Immediate-release azithromycin will probably become available generically later this year when its patent expires.

Med Lett Drugs Ther. 2005 Sep 28;47(1218):78-80 |  Show IntroductionHide Introduction

Pioglitazone/Metformin (Actoplus met)

   
The Medical Letter on Drugs and Therapeutics • Jan 30, 2006  (Issue 1227)
., Vanderbilt School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D ...
For patients with diabetes poorly controlled with a single oral drug, addition of a second drug with a different mechanism can be helpful. A fixed-dose combination (Actoplus met - Takeda) of two widely used antihyperglycemic drugs, the thiazolidinedione pioglitazone (Actos) and the biguanide metformin (Glucophage, and others), has been approved by the FDA for management of type 2 diabetes. It is indicated for patients already being treated with both pioglitazone and metformin or as second-line therapy for those not adequately controlled with either metformin or pioglitazone alone....
Med Lett Drugs Ther. 2006 Jan 30;48(1227):9-11 |  Show IntroductionHide Introduction

Intra-Articular Injections for Osteoarthritis of the Knee

   
The Medical Letter on Drugs and Therapeutics • Mar 27, 2006  (Issue 1231)
., Vanderbilt School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D ...
Now that glucosamine and chondroitin, 2 favorite over-the-counter remedies for painful osteoarthritis (OA) of the knee, have been at least somewhat discredited, some patients will be asking about alternatives. One of these is periodic intra-articular injection of a corticosteroid or hyaluronic acid preparation.
Med Lett Drugs Ther. 2006 Mar 27;48(1231):25-7 |  Show IntroductionHide Introduction

Inhaled Insulin (Exubera)

   
The Medical Letter on Drugs and Therapeutics • Jul 17, 2006  (Issue 1239)
R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D., New York University School ...
An inhaled, dry-powder formulation of rapid-acting human insulin (Exubera - Pfizer) has been approved by the FDA for treatment of adults with type 1 or type 2 diabetes.
Med Lett Drugs Ther. 2006 Jul 17;48(1239):57-8 |  Show IntroductionHide Introduction

Automated External Defibrillators

   
The Medical Letter on Drugs and Therapeutics • Aug 14, 2006  (Issue 1241)
Hospital, Copenhagen Dan M. Roden, M.D., Vanderbilt University School of Medicine F. Estelle R. Simons ...
Sudden cardiac arrest has a survival rate of about 6% without immediate defibrillation. Automated external defibrillators (AEDs) can be found in many public locations such as shopping malls, office buildings and schools. Some patients may ask their physicians whether they should purchase an AED for personal use. One device has been FDA-approved for sale over the counter (HeartStart Home Defibrillator - Philips). Purchase of all other AEDs for public places or home use requires authorization from a physician.
Med Lett Drugs Ther. 2006 Aug 14;48(1241):71-2 |  Show IntroductionHide Introduction

Ranibizumab (Lucentis) for Macular Degeneration

   
The Medical Letter on Drugs and Therapeutics • Oct 23, 2006  (Issue 1246)
Hospital, Copenhagen Dan M. Roden, M.D., Vanderbilt University School of Medicine F. Estelle R. Simons ...
The FDA has approved ranibizumab (Lucentis - Genentech) as an intravitreal injection for treatment of neovascular (wet) age-related macular degeneration (AMD). Ranibizumab is a derivative of bevacizumab (Avastin), which is FDA-approved for intravenous treatment of metastatic colorectal cancer and nonsmall cell lung cancer, but has also been used off label for intravitreal treatment of neovascular AMD.
Med Lett Drugs Ther. 2006 Oct 23;48(1246):85-6 |  Show IntroductionHide Introduction